AGM
NKTR icon

Alpine Global Management’s Nektar Therapeutics NKTR Stock Holding History

Alpine Global Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,678
Closed -$217K – 351
2024
Q2 		$217K Buy
+11,678
New +$246K 0.04% 294
2023
Q1 		– Sell
-3,671
Closed -$124K – 321
2022
Q4 		$124K Buy
+3,671
New +$178K 0.04% 132
2022
Q3 		– Sell
-680
Closed -$39K – 487
2022
Q2 		$39K Buy
+680
New +$42.9K 0.01% 174
2018
Q2 		– Sell
-1,192
Closed -$1.9M – 97
2018
Q1 		$1.9M Buy
+1,192
New +$1.54M 0.45% 35

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Alpine Global Management's NKTR Position: Q3 2024 in Review

Alpine Global Management sold out of Nektar Therapeutics (NKTR) in Q3 2024, closing a stake of 11,678 shares — an estimated $217K sold.

Alpine Global Management first reported a position in NKTR in Q1 2018 and held it in 4 quarters. The position peaked at $1.9M in Q1 2018. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2024.

  • Alpine Global Management reported no remaining Nektar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 11,678 Nektar Therapeutics shares in Q3 2024, an estimated $217K.
  • Alpine Global Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 4 quarters.
  • Alpine Global Management's Nektar Therapeutics position peaked at $1.9M in Q1 2018.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.